Lipocine has been granted a patent for bioavailable solid state esters of (17-ß)-Hydroxy-4-Androsten-3-one for pharmaceutical use. The patent covers compositions to treat testosterone deficiency in mammals, including those with complete absence of endogenous testosterone. GlobalData’s report on Lipocine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lipocine, Nanoparticle drug conjugates was a key innovation area identified from patents. Lipocine's grant share as of January 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating testosterone deficiency
A recently granted patent (Publication Number: US11872235B1) discloses a pharmaceutical composition containing a crystalline form of (17-ß)-3-Oxoandrost-4-en-17-yl tridecanoate with a melting point between 68-75°C. The composition, fully or partially dissolved in a lipophilic surfactant, includes the active ingredient in an amount ranging from 250 mg to about 350 mg. Additionally, the formulation may also contain a pharmaceutically acceptable carrier with a hydrophilic surfactant, such as polyethylene glycol, and can be presented in the form of a capsule or tablet.
Furthermore, the patent claims specify various formulations and release characteristics of the pharmaceutical composition. These include the use of specific lipophilic surfactants like fatty acids, monoglycerides, and diglycerides, as well as the release profile of the active ingredient over time. The compositions are designed to release a specific percentage of the (17-ß)-3-Oxoandrost-4-en-17-yl tridecanoate within defined time frames when tested under standardized conditions, ensuring optimal delivery and efficacy. The patent also highlights the use of these compositions in oral capsules for human administration, emphasizing the potential applications and benefits of this innovative pharmaceutical formulation.
To know more about GlobalData’s detailed insights on Lipocine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
